The percentage of general practices in the UK operating their own prescribing formularies is expected to rise to 43% over the next year from around 25% at present, according to a new report published by market research specialists Milpro.
Approximately two-thirds of the Family Health Services Authority pharmaceutical advisers questioned in the study said that the most important factors to be considered when advising general practitioners to include individual drug products in their formularies were efficacy and cost. Around 25% of the advisers told the study that they would urge GPs to include generic products only in their practice formularies, and to exclude brand-name drugs completely.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze